HTG Molecular Diagnostics ($HTGM) announced inking a new master services agreement with Daiichi Sankyo Company relating to HTG’s VERI/O laboratory. The deal involves the development of a custom assay for the detection of nearly 3,000 mRNA targets using the HTG EdgeSeq technology.
Cardinal Health ($CAH) has signed a new deal with Medtronic for acquiring its Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion. The deal will be immediately accretive by more than $0.21 to fiscal 2018 non-GAAP EPS, including $100M of inventory step-up costs during the first several quarters, and $0.55 to non-GAAP EPS in fiscal 2019. The transaction will be financed with cash on hand and $4.5 billion in new senior unsecured debt.